Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+, Mozilla Firefox 20+, Internet Explorer 11, Opera 15–18, Apple Safari 7, SeaMonkey 2.15-2.23

Seagen - ADCs’ Potential Across Tumors

Closing Remarks

Date

22 Oct 2023

Session

Seagen - ADCs’ Potential Across Tumors

Topics

Cytotoxic Therapy; Targeted Therapy

Tumour Site

Presenters

Josep Tabernero

Authors

J. Tabernero

Author affiliations

Medical Oncology Dept., Vall d'Hebron University Hospital, 8035 - Barcelona/ES

Resources

This content is available to ESMO members and event participants.

Login

Resources from the same session

22 Oct 2023

Welcome and Introduction

Presenter: Josep Tabernero

Session: Seagen - ADCs’ Potential Across Tumors

Resources:

Webcast

22 Oct 2023

ADC Technologies in Oncology

Presenter: Josep Tabernero

Session: Seagen - ADCs’ Potential Across Tumors

Resources:

Webcast

22 Oct 2023

Emerging ADCs in Non-Small Cell Lung Cancer

Presenter: David Planchard

Session: Seagen - ADCs’ Potential Across Tumors

Resources:

Webcast

22 Oct 2023

Advances in ADCs for Head and Neck Cancer

Presenter: Laura Locati

Session: Seagen - ADCs’ Potential Across Tumors

Resources:

Webcast

22 Oct 2023

Future Directions for ADCs in Urothelial Cancer

Presenter: Thomas Powles

Session: Seagen - ADCs’ Potential Across Tumors

Resources:

Webcast

22 Oct 2023

Panel Discussion and Audience Q&A

Presenter: All Speakers

Session: Seagen - ADCs’ Potential Across Tumors

Resources:

Webcast